Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Fuller, Deborah Heydenburg ^a,b,c,f   Rajakumar, Premeela ^a   Che, Jenny W ^a,c   Narendran, Amithi ^b   Nyaundi, Julia ^a   Michael, Heather ^a   Yager, Eric J ^b,g   Stagnar, Cristy ^b   Wahlberg, Brendon ^a   Taber, Rachel ^a   Haynes, Joel R ^c,h   Cook, Fiona C ^d   Ertl, Peter ^d   Tite, John ^d,i   Amedee, Angela M ^e   Murphey Corb, Michael ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c PowderJect Vaccines Inc   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^h LigoCyte Pharmaceuticals Inc   (United States)

ⁱ Babraham Research Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; LOPINAVIR PLUS RITONAVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TENOFOVIR; TRIPARTITE MOTIF PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DNA IMMUNIZATION; HAPLOTYPE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; INTESTINE FUNCTION; INTESTINE LYMPHATIC TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; RHESUS MONKEY; T LYMPHOCYTE; VIRUS LOAD; VIRUS RELEASE; VIRUS RESISTANCE; ANIMAL; IMMUNIZATION; IMMUNOLOGY; MACACA MULATTA; METHODOLOGY; MICROBIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; IMMUNIZATION; INTERFERON-GAMMA; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINES, DNA;

EID: 84858645007     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033715     Document Type: Article

References (68)

1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
2. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94: 13193-13197.
3. Staszewski S, Miller V, Sabin C, Berger A, Hill AM, et al. (1998) Rebound of HIV-1 viral load after suppression to very low levels. Aids 12: 2360.
4. Gandhi RT, Walker BD, (2002) Immunologic control of HIV-1. Annu Rev Med 53: 149-172.
5. Lu W, Wu X, Lu Y, Guo W, Andrieu JM, (2003) Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9: 27-32.
6. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, et al. (2008) Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 4: e1000055.
7. Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, et al. (2000) Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 6: 1140-1146.
8. Fuller DH, Shipley T, Allen TM, Fuller JT, Wu MS, et al. (2007) Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 364: 245-255.
9. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, et al. (2007) Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 81: 1972-1979.
10. Levy Y, Gahery-Segard H, Durier C, Lascaux AS, Goujard C, et al. (2005) Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids 19: 279-286.
11. Lu W, Arraes LC, Ferreira WT, Andrieu JM, (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10: 1359-1365.
12. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, et al. (2005) Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23: 4292-4301.
13. Lackner AA, Veazey RS, (2007) Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 58: 461-476.
14. Wang X, Rasmussen T, Pahar B, Poonia B, Alvarez X, et al. (2007) Massive infection and loss of CD4+ T cells occurs in the intestinal tract of neonatal rhesus macaques in acute SIV infection. Blood 109: 1174-1181.
15. Donnelly JJ, Ulmer JB, Liu MA, (1997) DNA vaccines. Life Sci 60: 163-172.
16. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, et al. (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
17. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
18. Boyer JD, Maciag PC, Parkinson R, Wu L, Lewis MG, et al. (2006) Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine 24: 4498-4502.
19. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, et al. (1998) Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72: 10180-10188.
20. Kim JJ, Yang JS, Nottingham LK, Lee DJ, Lee M, et al. (2001) Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization. Virology 285: 204-217.
21. Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, et al. (1999) Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5: 526-534.
22. Fuller DH, Rajakumar PA, Wilson LA, Trichel AM, Fuller JT, et al. (2002) Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76: 3309-3317.
23. Amedee AM, Lacour N, Gierman JL, Martin LN, Clements JE, et al. (1995) Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. J Virol 69: 7982-7990.
24. Enioutina EY, Visic D, Daynes RA, (2000) The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18: 2753-2767.
25. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, et al. (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161: 3211-3214.
26. Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, et al. (2002) Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 76: 4536-4546.
27. Murphey-Corb M, Wilson LA, Trichel AM, Roberts DE, Xu K, et al. (1999) Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J Immunol 162: 540-549.
28. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
29. Riddler SA, Mellors JW, (1997) HIV-1 viral load and clinical outcome: review of recent studies. Aids 11 (Suppl A): S141-148.
30. Seman AL, Pewen WF, Fresh LF, Martin LN, Murphey-Corb M, (2000) The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol 81: 2441-2449.
31. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, et al. (1997) Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 71: 284-290.
32. Fuller DH, Rajakumar PA, Wu MS, McMahon CW, Shipley T, et al. (2006) DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348: 200-215.
33. Mudd PA, Ericsen AJ, Price AA, Wilson NA, Reimann KA, et al. (2011) Reduction of CD4+ T cells in vivo does not affect virus load in macaque elite controllers. J Virol 85: 7454-7459.
34. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 8.
35. Lim SY, Rogers T, Chan T, Whitney JB, Kim J, et al. (2010) TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog 6: e1000738.
36. Sauermann U, Siddiqui R, Suh YS, Platzer M, Leuchte N, et al. (2008) Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes and immunity 9: 69-80.
37. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
38. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, et al. (2005) Control of viral rebound through therapeutic immunization with DermaVir. Aids 19: 35-43.
39. zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, et al. (2008) A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses 24: 1103-1116.
40. Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, et al. (2002) Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. Journal of immunology 169: 5347-5357.
41. Chen D, Periwal SB, Larrivee K, Zuleger C, Erickson CA, et al. (2001) Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 75: 7956-7965.
42. Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, et al. (2010) GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5: e11021.
43. Rollman E, Smith MZ, Brooks AG, Purcell DF, Zuber B, et al. (2007) Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol 179: 4571-4579.
44. Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, et al. (2008) With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 82: 11181-11196.
45. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA, (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113: 998-1007.
46. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA, (2007) A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 178: 7211-7221.
47. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, et al. (2009) Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 83: 2201-2215.
48. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA, (2008) Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 381: 106-115.
49. Daynes RA, Enioutina EY, Butler S, Mu HH, McGee ZA, et al. (1996) Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect Immun 64: 1100-1109.
50. Enioutina EY, Bareyan D, Daynes RA, (2008) TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 26: 601-613.
51. Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, et al. (2004) Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72: 1019-1028.
52. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG, (1998) Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 187: 1647-1657.
53. Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, et al. (2006) Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107: 3258-3264.
54. Haynes JR, Arrington J, Dong L, Braun RP, Payne LG, (2006) Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 24: 5016-5026.
55. Wilson SJ, Webb BL, Maplanka C, Newman RM, Verschoor EJ, et al. (2008) Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol 82: 7243-7247.
56. Takeuchi H, Matano T, (2008) Host factors involved in resistance to retroviral infection. Microbiol Immunol 52: 318-325.
57. Taber R, Rajakumar PA, Fuller DH, Trichel AM, Dowling P, et al. (2006) Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. Virology 354: 116-131.
58. Nakajima T, Kimura A, (2008) Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART. Pharmacogenomics 9: 1347-1351.
59. Wu JQ, Dyer WB, Chrisp J, Belov L, Wang B, et al. (2008) Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy. Retrovirology 5: 24.
60. Martin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, Baskin GB, (1993) Effects of initiation of 3′-azido,3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 168: 825-835.
61. Brenchley JM, Douek DC, (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
62. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998) Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427-431.
63. Verhoeven D, Sankaran S, Silvey M, Dandekar S, (2008) Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 82: 4016-4027.
64. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, Watkins DI, (1997) A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50: 657-661.
65. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, et al. (1995) Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430.
66. Fuller DH, Murphey-Corb M, Clements J, Barnett S, Haynes JR, (1996) Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J Med Primatol 25: 236-241.
67. Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, et al. (2003) Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 77: 13348-13360.
68. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12 Unit 12 11.